Gene · 2122
Papers2,623
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,623
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mutant ASXL1 Cooperates with MECOM and BRD4 to Drive Transcriptional Dysregulation in Human Hematopoiesis. | Blood | 2026 | 42771583 | PubTator, text mining | PubMed |
Successful induction of remission with azacitidine, venetoclax, and dasatinib followed by allogeneic hematopoietic stem cell transplantation in a patient with Philadelphia chromosome-positive mixed phenotype acute leukemia (B/myeloid): a case report. | Front Med (Lausanne) | 2026 | 42746482 | PubTator, text mining | PubMed |
| Mutational Landscape and Clonal Dynamics in AML Undergoing PTCy Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2026 | 42727885 | PubTator, text mining | PubMed |
| Rare acute myeloid leukemia harboring BCR/ABL1 (P210), AML1-MDS1/EVI1, and AML1/EAP: case report and literature review. | Front Oncol | 2026 | 42694067 | PubTator, text mining | PubMed |
| Structural complexity and mechanistic diversity of MECOM rearrangements in myeloid neoplasms. | Pathology | 2026 | 42562659 | PubTator, text mining | PubMed |
| Optical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of MECOM rearrangements cryptic to conventional karyotype. | Am J Clin Pathol | 2026 | 42551945 | PubTator, text mining | PubMed |
| [Analysis of Genetic Characteristics and Clinical Efficacy in Pediatric Acute Myeloid Leukemia with NUP98∷KDM5A Fusion Gene Positive]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2026 | 42544647 | PubTator, text mining | PubMed |
| A Mecom-Cdk6 toggle switch governs hematopoietic stem-to-multipotent fate transitions via distinct multistable landscapes. | bioRxiv | 2026 | 42427749 | PubTator, text mining | PubMed |
| Knockdown of LINC01234 suppresses radiation-induced bystander cell ferroptosis through the MECOM-MAPK signaling pathway. | Sci Rep | 2026 | 42399315 | PubTator, text mining | PubMed |
| Therapy-related AML with MECOM rearrangement, biallelic TP53 inactivation, and striking nuclear abnormalities. | Blood | 2026 | 42390869 | PubTator, text mining | PubMed |
| Genomic Characterization of Classic Adamantinoma, Osteofibrous Dysplasia, and Osteofibrous Dysplasia-like Adamantinoma. | Mod Pathol | 2026 | 42379271 | PubTator, text mining | PubMed |
| AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia. | Br J Haematol | 2026 | 42241446 | PubTator, text mining | PubMed |
| Optical genome mapping in myeloid neoplasms. | Hum Pathol | 2026 | 42217833 | PubTator, text mining | PubMed |
| The MCU-MECOM Axis Orchestrates Glioblastoma Progression by Remodeling Mitochondrial Dynamics and Quality Control via MAMs. | Int J Biol Sci | 2026 | 42212314 | PubTator, text mining | PubMed |
| Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group. | Am J Hematol | 2026 | 42187108 | PubTator, text mining | PubMed |
| [Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | 42161656 | PubTator, text mining | PubMed |
| Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study. | Nat Commun | 2026 | 42151180 | PubTator, text mining | PubMed |
| Comprehensive Molecular Characterization of High-Grade Endometrial Cancer in an Ancestrally Diverse Cohort. | bioRxiv | 2026 | 42146380 | PubTator, text mining | PubMed |
| Corrigendum to "Genetic variation at the MECOM locus shaping human disease pathogenesis" [Volume 282, June 2026, 109027]. | Pharmacol Ther | 2026 | 42120240 | PubTator, text mining | PubMed |
| All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review. | Front Oncol | 2026 | 42063737 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2122/papers